LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun ...

Getting the Shingrix vaccine after the age of 50 can reduce your chances of developing the painful skin condition known as ...

GSK (GSK) announced that the European Medicines Agency, EMA, has accepted for review the regulatory application of a prefilled syringe ...

EMA accepts for review regulatory application of GSK’s Shingrix new prefilled syringe presentation for prevention of shingles: London, UK Wednesday, January 29, 2025, 13:00 Hrs ...

The FDA will review a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).

Shingrix was hit hard in the first quarter as a result of the prioritisation of COVID-19 vaccination programmes in the US and other markets, with sales dropping almost 50% to £327 million, but ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of a prefilled syringe presentation of Shingrix (GSK’s Recombinant ...

Shingrix grew 19% to £833 million in the quarter, backed up by solid performances for meningitis vaccines Bexsero and Menveo, which rose 34% to £218 million and 40% to £59 million, respectively.

GSK and the University of Oxford have entered a new research partnership to launch an immuno-prevention programme.

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the regulatory application of ...

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

LONDON - GlaxoSmithKline PLC (LSE/NYSE: NYSE:GSK) announced today that the European Medicines Agency (EMA) has begun reviewing a prefilled syringe form of Shingrix, GSK's vaccine for shingles ...